| Product Unit Size | Cost | Quantity | Stock |
|---|
Ranolazine exhibits anti-anginal, anti-arrhythmic, and cardioprotective activities; it is clinically used to treat angina pectoris. Ranolazine inhibits the late Na+ current (Nav1.7 and Nav1.7 channels) and subsequent intracellular Ca2+ accumulation. In hypertensive rats, ranolazine decreases end diastolic pressure, improving diastolic function and decreasing free Ca2+ levels. In other animal models, ranolazine inhibits induction of atrial flutter and atrial fibrillation.
| Cas No. | 95635-56-6 |
|---|---|
| Purity | ≥98% |
| Formula | C24H33N3O4 • 2HCl |
| Formula Wt. | 500.47 |
| Chemical Name | N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide dihydrochloride |
| IUPAC Name | N-(2, 6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin- 1-yl]acetamide;dihydrochloride |
| Synonym | RS-43285 |
| Melting Point | 164-166°C |
| Solubility | Soluble in water. |
| Appearance | A White or Almost White Crystalline Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Tocchetti CG, Carpi A, Coppola C, et al. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail. 2014 Jan 6. [Epub ahead of print]. PMID: 24464789.
Aldakkak M, Stowe DF, Camara AK. Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris. Clin Med Insights Ther. 2013 Jan 15;2013(5):1-14. PMID: 24574825.
Aidonidis I, Doulas K, Hatziefthimiou A, et al. Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits. J Cardiovasc Pharmacol Ther. 2013 Jan;18(1):94-101. PMID: 22872232.